R
Remedium bio
Adjustable, single-injection gene therapies for durable protein expression
About Remedium bio
Remedium Bio is a biotechnology company developing durable protein therapeutics based on an adjustable gene therapy platform. Its proprietary Prometheus platform is designed to enable controlled, long-lasting expression of therapeutic proteins after a minimally invasive subcutaneous injection, using adipocytes (fat cells) as a durable production site, with the potential for multi-year benefit and simple post-treatment dose adjustment. The aim is to replace many frequently injected protein therapies with single-injection gene therapies at a fraction of the cost. Remedium's pipeline spans cardiometabolic and endocrine diseases as well as immunology, neurology and musculoskeletal indications. The company is led by Chief Executive Officer Frank Luppino. On 10 August 2026 Lifespan Vision Ventures announced that it is leading Remedium's $10 million Series A financing and had completed the round's initial closing, with participation from Eli Lilly and Company and HKX Capital; Harry Robb of Lifespan Vision Ventures joined the board. The financing supports advancement of its lead programmes, platform expansion and preparation for first-in-human clinical studies. Sources: PR Newswire 10 Aug 2026; remedium-bio.com.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2026 | $10M | $40M | Eli Lilly · LifeSpan Vision Ventures | ↗ |
| EARLY VC✓Equity / VC | Sep 2024 | $0 | — | LifeSpan Vision Ventures | ↗ |
Growth signals
Latest recorded traffic for Remedium bio is 1.5K monthly website visits, down 40% over the last three months. Remedium bio's team grew 18.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Remedium bio in the Needham ecosystem
The Remedium bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed8 investors entered at this stage
LongevityTech.fund- SVSherwood Ventures
MicroVentures
Primo Medical Group- GAGuindy Alumni Angels
Angel Star Ventures
Apis Health Angels
US National Science Foundation
Series A2 investors entered at this stage
LifeSpan Vision Ventures
Eli Lilly
Other known investors4 additional known investors
- ABAntoni Bertel
SeedFolio
TEAM SYUlu Ventures
Source: Dealroom Talent Intelligence.
See Remedium bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









